Anteris Technologies Global Corp. (AVR) Stock Research

Anteris Technologies Global Corp.

· AVR

Dashboard

Financials

Ratios

Valuation

Statistics

739.71 M

+2.37%

Over a week ago

Anteris Technologies files to sell 5.39M shares of common stock

Jul 1, 5:14 PM

Anteris Technologies cleared by ANSM for DurAVR THV trial

Jun 8, 6:05 AM

Anteris Technologies price target raised by $1 at Barclays, here's why

May 15, 4:51 AM

Anteris Technologies: First U.S. patients treated in global PARADIGM trial

May 5, 6:28 AM

Anteris Technologies secures CMS reimbursement for trial site activation

Apr 28, 6:28 AM

Anteris Technologies participates in a conference call with Cantor Fitzgerald

Mar 24, 3:38 PM

Anteris Technologies assumed with an Overweight at Cantor Fitzgerald

Mar 12, 7:34 AM

Anteris Technologies initiated with bullish view at Wells Fargo, here's why

Mar 11, 6:56 AM

Anteris Technologies reports FY25 R&D expenses $69.1M

Feb 26, 6:01 PM

Anteris Technologies price target lowered by $5 at Barclays, here's why

Feb 23, 9:20 AM

Largest borrow rate increases among liquid names

Feb 11, 8:45 AM

Anteris Technologies price target lowered to $15 from $20 at Lake Street

Jan 23, 8:57 AM

Ten new option listings and two option delistings on January 22nd

Jan 22, 8:30 AM

Anteris Technologies 34.8M share Spot Secondary priced at $5.75

Jan 21, 6:04 AM

Anteris Technologies announces $200M common stock offering

Jan 20, 4:06 PM

Anteris Technologies files $500M mixed securities shelf

Jan 2, 5:20 PM

Anteris Technologies files to sell 9.1M shares of common stock for holders

Nov 26, 4:36 PM

Anteris Technologies Presents Data from 100 DurAVR(R) THV Patients at PCR London

Nov 17, 6:08 AM

Anteris Technologies receives FDA approval to initiate PARADIGM trial

Nov 3, 7:17 AM

Anteris Technologies reports clinical outcomes for DurAVR THV in patients

Oct 28, 6:18 PM

Anteris Technologies treats first patient in DurAVR heart valve pivotal trial

Oct 27, 5:47 PM

Anteris Technologies to present on one-year outcomes for DurAVR THV

Oct 27, 8:48 AM

Anteris receives first European regulatory clearance to commence DurAVR trial

Oct 15, 9:22 AM

Charts